Korean J Obstet Gynecol.  2002 Sep;45(9):1505-1510.

Loss of Heterozygosity using Microsatellite Marker in plasma of patients with ovarian cancer

• Kim YM
• Kim YT
• Lee KW

Abstract

OBJECTIVE
Recent studies demonstrated that soluble tumor DNA is found in the plasma of cancer patients, and some microsatellite alteration have been identified in ovarian carcinoma. The aim of study was to detect microsatellite abnormalities in the plasma of patients with ovarian carcinoma and to evaluate their efficacy as molecular screening or diagnostic tool for ovarian cancer.
METHODS
In fifteen ovarian carcinoma patients, DNA was extracted from the plasma samples and microsatellite analysis was done with 11 microsatellite markers.
RESULTS
All fifteen cases showed at least one tumor specific alteration in microsatellite analysis. The frequency of genetic alteration varies from 14.2% to 85.7%. Highly frequent tumor specfic alteration markers are D18S69 (85.7%), D10S215 (69.2%), D16S504 (66.7%), D8SNEFL (62.5%) and D11S1340 (60.0%).
CONCLUSION
These results suggest that the mutation of tumor DNA can be detected in plasma of patients with ovarian carcinoma. LOH is more frequent event and the frequency of genetic alteration is relatively higher than that of previous reports.

Keyword

Loss of heterozygosity; Microsatellite instability; Ovarian cancer; Plasma DNA

MeSH Terms

DNA
Humans
Loss of Heterozygosity*
Mass Screening
Microsatellite Instability
Microsatellite Repeats*
Ovarian Neoplasms*
Plasma*
DNA